Nombre del producto:1-Fluoro-2-methyl-4-nitrobenzene

IUPAC Name:1-fluoro-2-methyl-4-nitrobenzene

CAS:455-88-9
Fórmula molecular:C7H6FNO2
Pureza:95%+
Número de catálogo:CM253045
Peso molecular:155.13

Unidad de embalaje Stock disponible Precio($) Cantidad
CM253045-500g in stock ǵǵNJ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :455-88-9
Fórmula molecular:C7H6FNO2
Punto de fusión:-
Código de sonrisas:O=[N+](C1=CC=C(F)C(C)=C1)[O-]
Densidad:
Número de catálogo:CM253045
Peso molecular:155.13
Punto de ebullición:223°C at 760 mmHg
Nº Mdl:MFCD00007284
Almacenamiento:Store at 2-8°C.

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Zongertinib
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients.
Zongertinib (also known as BI 1810631) is an investigational oral HER2-specific tyrosine kinase inhibitor (TKI) that is being developed as a potential treatment for HER2 mutated non-small cell lung cancer (NSCLC). Zongertinib was granted FDA Fast Track Designation in 2023, then in 2024 it was granted Breakthrough Therapy Designation by the U.S. FDA and China CDE for the treatment of adult patients with advanced NSCLC whose tumors have activating HER2 mutations, and who have received a prior systemic therapy.